Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus

Abstract

ObjectiveThe authors documented the localization and frequency of lymphatic spread in squamous cell carcinoma of the thoracic esophagus and evaluated the influence of radical systematic lymph node dissection on patient survival. Summary Background Data ResultsComparative study revealed that 5-year survival rate for TNM RO patients after three-field dissection (55.0%) was significantly better (log rank test, p = 0.0013) than the rate after two-field dissection (38.3%). The results were particularly significant in subgroups with stage I l I l and IV (because of nodal factor). Overall 5-year survival rate after all resections was 42.4%. ConclusionsThe role of radical lymph node dissection in cancer of the thoracic esophagus was evaluated. Long-term survival was compared between two groups with two-and three-field dissection. It was concluded that survival rate was significantly better in patients with extensive three-field dissection.The aim of this study was to analyze the effect of pro-study of depth of tumor and the status of each dissected phylactic radical systematic lymph node dissection on node. the survival of patients with squamous cell carcinoma of Our previous routine procedure was to dissect only the the thoracic esophagus. The deta are based on accurate mediastinal and abdominal nodes. During this period, we documentation of tumor spread with histopathologic noted that some cases with tumor recurrence in the cervical 364

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

“…Most patients with oesophageal cancer in Japan have squamous cell carcinoma (SCC), while most of those in Western countries have adenocarcinoma. Despite improvements in surgical techniques and perioperative management (Akiyama et al, 1994;Ando et al, 2000), and surgery combined with chemotherapy (Ando et al, 2003) and/or radiotherapy (Ishikura et al, 2003), the prognosis remains poor. Therefore, for oesophageal SCC patients, novel therapies such as molecular-targeted therapy, including small molecule inhibitors of tyrosine kinases or humanised monoclonal antibodies, are very much needed.…”

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma

“…Despite various treatments such as surgical resection with extensive lymphadenectomy (Maillet et al, 1982;Altorki and Skinner, 1990;Kato et al, 1991;Akiyama et al, 1994) and the surgery combined with chemotherapy (Hayashi et al, 2001) and/or radiotherapy (Le Prise et al, 1995;Adham et al, 2000;Ishikura et al, 2003), the prognosis for advanced patients with oesophageal SCC remains poor. The utilisation of antitumour T cells or antibodies against tumour antigens, as immunoadjuvant therapy for oesophageal SCC, is therefore an attractive approach.…”

Extranodal connective tissue invasion and the expression of desmosomal glycoprotein 1 in squamous cell carcinoma of the oesophagus

“…Although the prognosis of patients with oesophageal carcinoma has been improved by the use of extended lymph node dissections (Siewert and Roder, 1992;Akiyama et al, 1994, the incidence of recurrence is still high (Sugimachi et al, 1983;Chan et al, 1986;Natsugoe et al, 1994). Even if metastatic lymph nodes are removed surgically, some patients will have locoregional recurrence.…”